原有业务陷入增长瓶颈，爱博医疗（688050.SH）向外拓展寻求突破。 2月25日晚间，爱博医疗发布收购计划，拟使用并购贷款及自有资金，作价6.83亿元收购德美联合（重 庆）医疗科技有限公司（以下简称"德美医疗"）68.31%股权。交易完成后，德美医疗将成为爱博医疗的 控股子公司。 据了解，德美医疗是国内运动医学的头部企业。通过此次收购，爱博医疗将从眼科医疗器械领域拓展至 运动医学领域，培育新的盈利增长点。 数据显示，2025年前三季度，爱博医疗实现营业收入11.44亿元，同比增长6.43%；归母净利润和扣非净 利润分别为2.9亿元、2.8亿元，同比下降8.64%、8.14%，明显出现增收不增利的现象。 长江商报记者注意到，本次交易中，德美医疗整体估值达10.74亿元，评估增值率343.29%。交易完成之 后，爱博医疗预计将新增5亿元商誉。 尽管德美医疗的创始股东作出未来三年净利润累计不低于1.65亿元的业绩承诺，但如果未来德美医疗业 绩不及预期，爱博医疗仍将存在商誉减值的风险。 此外，本次交易对价的70%至80%均由爱博医疗以贷款方式筹得，预计将使公司合并报表层面新增一定 规模的有息负债，未来的财务负担亦不 ...

据此前招股书，天星医疗是一家专注于运动医学整体临床解决方案的创新型医疗器械公司。据灼识咨询数据，按2024年销售收入计，天星医疗是中国最大的 国产运动医学公司。 截至最后实际可行日期，天星医疗拥有国内最全面的运动医学产品，主要涵盖植入物、有源设备及相关耗材、手术工具等52款产品，可以提供整体临床运动 医学解决方案。第三类医疗器械20款，5款产品在中国市场上所有品牌中首个获批并应用于临床，10款产品在国产品牌中首个获批并应用于临床。此外，天 星医疗在运动医学及智能康复领域的在研产品超过35个。 于往绩记录期间，依托多元化的产品矩阵，公司在中国市场实现了深度渗透：截至2022年12月31日，公司的产品已经进入医院数量超过1,000家，截至2024 年12月31日已增至3,000余家，其中三级医院超过1,000家。 北京天星医疗股份有限公司(简称：天星医疗)于2025年8月26日所递交的港股招股书满6个月，于2026年2月26日失效，递表时中信证券、建银国际为其联席 保荐人。 | 26/08/2025 | 北京天星醫療股份有限公司 | | --- | --- | | | 09/09/2025 整體協調人公告 - 委 ...

智通财经APP获悉，北京天星医疗股份有限公司(简称：天星医疗)于2025年8月26日所递交的港股招股书满6个月，于2026年2月26日失效，递表时中信证券、 建银国际为其联席保荐人。 | 26/08/2025 | 北京天星醫療股份有限公司 | | --- | --- | | | 09/09/2025 整體協調人公告 - 委任（經修訂） 四 | | | 26/08/2025 申請版本（第一次呈交） 全文檔案 [四] 多檔案 | | | 前提交文件: | | | 26/08/2025 整體協調人公告 - 委任 吧 | 据此前招股书，天星医疗是一家专注于运动医学整体临床解决方案的创新型医疗器械公司。据灼识咨询数据，按2024年销售收入计，天星医疗是中国最大的 国产运动医学公司。 截至最后实际可行日期，天星医疗拥有国内最全面的运动医学产品，主要涵盖植入物、有源设备及相关耗材、手术工具等52款产品，可以提供整体临床运动 医学解决方案。第三类医疗器械20款，5款产品在中国市场上所有品牌中首个获批并应用于临床，10款产品在国产品牌中首个获批并应用于临床。此外，天 星医疗在运动医学及智能康复领域的在研产品超过35个。 于往绩 ...

Core Viewpoint - Aibo Medical has signed a Letter of Intent with Demei Medical to acquire at least 51% of its shares, with an estimated valuation of Demei Medical not exceeding 1 billion yuan, indicating a stable profit growth commitment from 2026 to 2028 [1][2] Acquisition Details - The acquisition is expected to be financed through a combination of self-funds and bank loans [1] - Demei Medical's preliminary valuation corresponds to a price-to-earnings (PE) ratio of approximately 22X, 18X, and 15X for the years 2026, 2027, and 2028 respectively [1] - Demei Medical's net profit commitments for 2026, 2027, and 2028 are projected to be 45 million, 55 million, and 65 million yuan, representing year-on-year growth rates of +28.5%, +22.2%, and +18.2% respectively [1] Company Profile - Demei Medical, established in 2015, is a leading brand in China's sports medicine sector, offering a comprehensive range of products including imaging equipment, surgical tools, implantable consumables, and rehabilitation devices [1] - The company has achieved significant breakthroughs in core technologies and has established a full industry chain layout, making it a representative manufacturer of sports medicine in China [2] Financial Performance - Demei Medical's projected revenues for 2023, 2024, and 2025 are 178 million, 236 million, and 286 million yuan, with year-on-year growth rates of +32.6% and +21.4% [2] - The adjusted net profits for the same years are expected to be -7.08 million, 9.29 million, and 23.60 million yuan, indicating a significant increase in profitability [2] International Expansion - Demei Medical has developed strong international capabilities, with a sales network covering over 50 countries and regions, and plans to participate in more than 10 international exhibitions and academic exchanges in 2025 [2] - The collaboration with Aibo Medical is expected to enhance its overseas business, which accounted for 5.5% of total revenue in the first half of 2025 [2] Profit Forecast and Investment Outlook - Aibo Medical is projected to achieve revenues of 1.572 billion, 1.823 billion, and 2.173 billion yuan from 2025 to 2027, with year-on-year growth rates of +11.5%, +16.0%, and +19.2% respectively [3] - The expected net profits for the same period are 414 million, 476 million, and 575 million yuan, with growth rates of +6.7%, +14.9%, and +20.7% respectively [3] - The current stock price corresponds to PE ratios of 29X, 25X, and 21X for the years 2025, 2026, and 2027 [3] Rating - The company maintains a "recommended" rating [4]

Investment Rating - The report maintains a "Buy" rating for the company [3] Core Views - The company plans to acquire a 51% stake in DeMei Medical, which is expected to become a new growth point in the medical training sector [8] - DeMei Medical is a leading brand in sports medicine in China, with a comprehensive product range covering pre-operative prevention, intra-operative treatment, and post-operative rehabilitation [8] - The acquisition is expected to directly contribute to profit growth, with DeMei Medical's projected net profits for 2026-2028 being 45 million, 55 million, and 65 million yuan, respectively, reflecting growth rates of 28.5%, 22.2%, and 18.2% [8] - The company is well-positioned for international expansion, with a sales network covering over 50 countries and a strong international presence [8] Financial Forecasts - Projected revenue for the company is expected to reach 1.41 billion yuan in 2024, growing to 2.17 billion yuan by 2027, with growth rates of 48.2%, 11.5%, 16.0%, and 19.2% for the respective years [2][9] - The net profit attributable to shareholders is forecasted to be 388 million yuan in 2024, increasing to 575 million yuan by 2027, with growth rates of 27.8%, 6.7%, 14.9%, and 20.7% [2][9] - Earnings per share are projected to rise from 2.01 yuan in 2024 to 2.97 yuan in 2027, with corresponding price-to-earnings ratios decreasing from 31 to 21 [2][9]

Core Viewpoint - Aibo Medical (688050.SH) plans to acquire at least 51% of Demai Medical, a leading sports medicine company, for a maximum valuation of 1 billion yuan, as a strategic move to diversify into the sports medicine sector amid challenges in its core ophthalmic business [3][12]. Group 1: Company Performance and Challenges - Aibo Medical has faced growth challenges, with its core artificial lens business, which has contributed nearly half of its revenue, experiencing pressure on profit margins due to price reductions following the inclusion in the national high-value medical consumables procurement [3][4]. - The sales volume of Aibo Medical's products increased by 44.93% in 2024, but revenue growth was only 17.66%, indicating a decline in average selling price from 437.56 yuan in 2022 to 338.06 yuan in 2024, with gross margin dropping from 84.75% in 2022 to 65.25% in the first half of 2025 [4][5]. - The company's stock price has significantly declined, dropping 49.94% from its peak of 117.65 yuan per share in October 2024 to a low of 58.89 yuan in December 2025, marking a new low since its listing [6][7]. Group 2: Market Dynamics and Competition - The OK lens business, seen as a potential growth driver, is facing intense competition from domestic players like Haohai Biological and Opcon Vision, leading to only single-digit growth in the near-sightedness prevention business in the first three quarters of 2025 [5]. - The strategic vision for the sports medicine market is promising, with an expected market size of 80-100 billion yuan by 2025, growing from 60-68 billion yuan in 2023, and a compound annual growth rate of 15%-20% [11]. Group 3: Acquisition Details and Financial Projections - Aibo Medical's acquisition target, Demai Medical, is a recognized domestic brand in sports medicine with a comprehensive product range and a strong patent portfolio, having transitioned from losses to profitability with adjusted net profits projected to grow significantly from 2023 to 2025 [12][13]. - The acquisition is structured with a performance commitment from Demai Medical's founder to achieve a cumulative net profit of at least 165 million yuan from 2026 to 2028, with specific annual targets [14]. - The valuation of 1 billion yuan corresponds to a price-to-earnings ratio of approximately 15.38 times based on the 2028 profit commitment, but this is significantly higher at 42.37 times based on the projected 2025 profit, indicating a high-risk investment [15]. Group 4: Integration Challenges and Risks - The integration of Aibo Medical and Demai Medical poses significant challenges due to differences in technology application, customer demographics, and clinical ecosystems, which may complicate the realization of synergistic benefits [16]. - Potential synergies exist in technology and sales channels, as Aibo Medical's expertise in biocompatible materials could enhance Demai Medical's product offerings, while their respective sales networks could support cross-promotion [17]. - Financial risks are present, with Demai Medical's liabilities increasing at a faster rate than revenue, and Aibo Medical's use of acquisition loans could heighten financial leverage, adding pressure if performance targets are not met [18].

Summary of the Conference Call Record Company Overview - **Company Name**: 德美医疗 (Demei Medical) - **Industry Focus**: Specializes in "Sports Medicine + Sports Health" as a technology-driven enterprise - **Business Scope**: Covers the entire chain from "preoperative prevention to surgical treatment to postoperative rehabilitation" - **Product Range**: 1. Sports medicine implants 2. Surgical tools 3. Arthroscopic equipment 4. Sports rehabilitation devices and equipment 5. Research, production, sales, and services - **Industry Position**: Leading enterprise in the domestic industry - **Procurement Qualification**: Selected for the National High-Value Medical Consumables Procurement Group A [1] Acquisition Details - **Valuation of Target Company**: Expected to be no more than RMB 1 billion - **Final Transaction Price**: To be determined based on asset appraisal report and due diligence results - **Acquisition Stake**: At least 51% equity - **Acquisition Goal**: To gain control of the target company [1] Financial Performance (Last Three Years) - **Revenue Growth**: - 2023: RMB 178 million - 2024: RMB 236 million - 2025: RMB 286 million - **Net Profit (Adjusted)**: - 2023: Loss of RMB 7.08 million - 2024: Profit of RMB 9.29 million - 2025: Profit of RMB 23.60 million [1]

Core Viewpoint - Aibo Medical announced plans to acquire at least 51% of Demai Medical, with an estimated valuation of the target company not exceeding 1 billion yuan [1] Company Summary - Demai Medical, founded in July 2016, has a registered capital of over 12.14 million yuan and is controlled by its founder and major shareholder, Li Jianbo, who holds 14.7994% of the shares [1] - The company has a strategic focus on the entire spectrum of sports health, including pre-surgery prevention, surgical treatment, and post-surgery rehabilitation, and operates as an international medical technology group [1][2] - As of the announcement date, Demai Medical has 276 authorized patents and has obtained various medical device registrations, including 34 Class III, 48 Class II, and 63 Class I medical device registration certificates [2] Industry Summary - The domestic sports medicine market is currently dominated by international brands, which hold approximately 80% market share, with major players including Stryker, Johnson & Johnson, and Arthrex [5] - The market size for sports medicine in China is projected to reach 8-10 billion yuan in 2025, with a compound annual growth rate of about 15%-20% [5] - The inclusion of sports-related injury implants in the national procurement plan in 2024 is expected to create opportunities for domestic companies to expand their market share and enhance industry influence [2] Financial Summary - As of the end of 2025, Demai Medical's total assets are projected to be 425 million yuan, with total liabilities of 160 million yuan and equity of 260 million yuan [3] - The expected revenue for 2025 is 286 million yuan, with an adjusted net profit of approximately 35.02 million yuan [3]

Core Perspective - Johnson & Johnson (J&J) is divesting its orthopaedics business, marking a significant strategic shift that could reshape the company and the broader market for joint replacements and related products [1][4]. Company Summary - J&J's orthopaedics division was developed over decades, known for its hip and knee replacements, spinal interventions, and surgical tools, contributing steady revenue but facing rising competition and regulatory costs [2][3]. - The decision to explore strategic alternatives for the orthopaedics business aims to unlock value by allowing J&J to focus on higher-growth areas such as pharmaceuticals and digital surgery [3]. Industry Summary - The divestment may lead to changes in pricing, product support, and innovation priorities for hospitals and surgeons, while potentially benefiting patients through renewed focus and investment in the orthopaedics sector [4]. - The move could trigger further consolidation in the orthopaedics market as buyers seek scale, and it may accelerate the shift towards value-based purchasing and tech-enabled surgical solutions [4].

Group 1 - Tianxing Medical has submitted an IPO application to the Hong Kong Stock Exchange, following a failed IPO attempt on the Shanghai STAR Market in June 2023, which has attracted significant market attention [1] - The company cited market conditions and lengthy approval processes as reasons for withdrawing its STAR Market application, although the termination was primarily due to the unilateral withdrawal by its sponsor, CICC [1] - The trend of sponsors unilaterally withdrawing IPO applications is becoming more common, as seen in the case of Dongfang Securities withdrawing the IPO application for Ningbo Zhongchun High-Tech Co., Ltd. earlier this year [1] Group 2 - Tianxing Medical has changed its sponsors for the Hong Kong IPO, appointing CITIC Securities and Jianyin International as joint sponsors [1] - The company specializes in sports medicine, with a product line that includes implants, active devices, consumables, and surgical tools [1] - In 2024, Tianxing Medical reported revenues of 327 million yuan and a net profit of 95 million yuan, representing year-on-year growth of 37.13% and 67.02%, respectively [1] Group 3 - Despite significant price declines, Tianxing Medical's product gross margin remains high, with the gross margin for implants at 72.4% in 2024, only a 6.6 percentage point decrease year-on-year [2] - The success of Tianxing Medical's second IPO attempt is a focal point for the market, as it will provide insights into the role and responsibilities of sponsors [5]